Commitments and Contingencies (Details) € in Millions, $ in Millions						1 Months Ended	9 Months Ended
	May 22, 2025 defendant	May 13, 2025 defendant	May 05, 2025 USD ($)	Mar. 26, 2025 defendant	Apr. 01, 2019 USD ($)	Apr. 30, 2020 USD ($)	Sep. 30, 2025 EUR (€) plaintiff
NAMENDA XR/Namzaric Qui Tam Litigation
Long-term Purchase Commitment [Line Items]
Loss contingency, damages sought, value					$ 2,500.0
Merger Agreement | Sage Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiff | plaintiff							2
Derivative Litigation | Sage Litigation
Long-term Purchase Commitment [Line Items]
Number of defendants | defendant	16	16		16
USWM Acquisition
Long-term Purchase Commitment [Line Items]
Annual minimum purchase quantity requirement amount | €							€ 3.0
Litigation settlement					$ 17.5
Navitor Pharmaceuticals, Inc.
Long-term Purchase Commitment [Line Items]
Collaborative arrangement agreement termination notice period						30 days
Threshold for development costs payments						$ 50.0
Collaborative arrangement, payment for one time fee						10.0
Collaborative arrangement, upfront development costs						25.0
Collaborative agreement, acquisition-related cost, expense			$ 100.0
Navitor Pharmaceuticals, Inc. | Minimum
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, expected development costs						410.0
Navitor Pharmaceuticals, Inc. | Maximum
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, expected development costs						475.0
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary
Long-term Purchase Commitment [Line Items]
Investments						$ 15.0
VIE, qualitative or quantitative information, ownership percentage						13.00%